KNSA KNSA
Company Profile ↓Company Overview
KNSA (KNSA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 104.8% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $677.56M (+60.1% YoY); net profit $59.01M.
- Trailing 12 Months Year-on-year growth — revenue +60.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 104.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 104.76% |
| 1 Year: | 60.09% |
Stock Price Performance
| 1 Year: | +136.97% |
| 6 Months: | +73.67% |
| 3 Months: | +37.61% |
| 1 Month: | +16.04% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)67.59 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 104.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 104.1.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 7.70M | 12.10M | 32.19M | 26.97M | 99.14M | 48.34M | 71.47M | 67.05M | 79.86M | 108.63M | 112.21M | 137.78M | 156.80M | 180.85M | 214.27M |
| Operating Income | -11.39M | -16.25M | -16.34M | -21.53M | -26.16M | -67.65M | -39.29M | -30.45M | -29.39M | -31.86M | -43.22M | -49.28M | -40.55M | -30.67M | -23.32M | -19.37M | 46.41M | -11.20M | -3.15M | -10.93M | -16.54M | -117.00K | -9.66M | 13.27M | 20.16M | 24.02M | 29.27M |
| Net Income | -11.20M | -16.03M | -15.98M | -20.26M | -24.41M | -65.82M | -37.19M | -27.06M | -26.42M | -37.47M | -43.84M | -49.48M | -41.56M | -30.54M | -25.21M | -19.98M | 224.09M | -12.27M | 14.97M | -13.86M | -17.70M | -3.91M | -12.69M | 8.54M | 17.83M | 18.43M | 22.59M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -0.72 | -0.61 | -0.44 | -0.36 | -0.29 | 3.18 | -0.18 | 0.21 | -0.20 | -0.25 | -0.06 | -0.18 | 0.11 | 0.23 | 0.23 | 0.27 |
| R&D Expense | 9.27M | 14.01M | 12.63M | 17.20M | 20.64M | 59.25M | 30.85M | 22.01M | 20.90M | 22.32M | 31.42M | 28.68M | 23.95M | 19.24M | 20.82M | 13.80M | 16.48M | 15.17M | 23.77M | 17.11M | 26.33M | 24.02M | 26.06M | 19.32M | 18.75M | 24.17M | 27.48M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 38.54M | 220.18M | 270.26M | 423.24M | 677.56M |
| Operating Income | -65.40M | -108.16M | -169.96M | -157.36M | -156.64M | 9.77M | -25.20M | -45.62M | 77.22M |
| Net Income | -64.87M | -103.23M | -161.87M | -161.38M | -157.92M | 183.36M | 14.08M | -43.19M | 59.01M |
| Diluted EPS | - | - | -2.99 | -2.61 | -2.30 | 2.60 | 0.20 | -0.60 | 0.75 |
| R&D Expense | 56.36M | 86.60M | 135.00M | 112.04M | 99.30M | 65.49M | 76.10M | 111.62M | 96.85M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 47.49M | 321.96M | 254.53M | 349.46M | 232.80M | 459.67M | 526.32M | 580.55M | 763.63M |
| Total Equity | -25.73M | -89.71M | 279.27M | 225.42M | 311.94M | 185.04M | 396.15M | 438.84M | 438.44M | 567.61M |
| Cash & Equivalents | - | 45.55M | 71.98M | 46.93M | 114.04M | 122.47M | 122.72M | 107.95M | 183.58M | 165.60M |
| Total Liabilities | - | 17.43M | 42.70M | 29.11M | 37.53M | 47.76M | 63.52M | 87.48M | 142.12M | 196.03M |
| Current Liabilities | - | 17.43M | 42.55M | 27.83M | 31.85M | 44.82M | 47.07M | 63.67M | 100.62M | 139.18M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -50.22M | -81.01M | -158.37M | -136.53M | -126.30M | 5.81M | 13.30M | 25.69M | 137.99M |
| Investing Cash Flow | -69.00K | -239.20M | 49.21M | -23.44M | 128.63M | -8.08M | -29.56M | 37.67M | -188.99M |
| Financing Cash Flow | 39.87M | 346.74M | 84.11M | 227.09M | 5.88M | 2.52M | 1.50M | 12.27M | 33.02M |
| Capital Expenditure | -69.00K | -5.29M | -3.20M | -283.00K | -415.00K | -105.00K | -130.00K | -277.00K | -1.57M |
| Free Cash Flow | -50.29M | -86.30M | -161.57M | -136.81M | -126.71M | 5.70M | 13.17M | 25.41M | 136.42M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -406.4% | 4.4% | -9.3% | -10.8% | 11.4% |
| Net Margin % | - | - | - | - | -409.7% | 83.3% | 5.2% | -10.2% | 8.7% |
| ROE % | 72.3% | -37.0% | -71.8% | -51.7% | -85.3% | 46.3% | 3.2% | -9.9% | 10.4% |
| ROCE % | -217.6% | -38.7% | -75.0% | -49.5% | -83.3% | 2.4% | -5.4% | -9.5% | 12.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KNSA
31,391 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Bought by Financial Enhancement Group LLC - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi-AFBVV95cUxQcWpOVXNRcHF5Ty1lQnF4MnRmOFAxUjBMS2dOcDhWdlpnMkR4ZWo2VDVERHdjVXFqeXljYXZVSmdubk16NVVJRkNzS0hZSWpMSF9YUzVaRk8yNElxNzBuUWViYkYwLWw4X2dsWGdqZFlLY1lWSjBPUng0R2c2WElXM1RtbzU2NWRSSzRjNm…
Kiniksa Pharmaceuticals (KNSA) Stock Cools As Raised Guidance Meets ARCALYST Reliance - webull.com
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTFBBVHNJNTNkMmw5QS1LWmlkZFp6bmVrZTdzcWxJaHhaX3ZxWFNOWjZBOVBmTUxFX2Fic1B4S3pZVXFaM2J4SzZ3dVY3dFhuWmxkQUdLMkdQMmo?oc=5" target="_blank">Kiniksa Pharmaceuticals (KNSA) Stock Cools As Ra…
Kiniksa Pharmaceuticals (KNSA) director converts 403 RSUs to shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxORUEzRGhUWEtSRmd4bkRSQ2pSeGMtTTVNd09xaXJlY1dCSlBWX3plUkx1Z1pMTndnM1VmZk52WFYwY0lzcldKRkJGU0pYMXgyeHYwWE5BcVZfMllqX3lDbkZ1dzViVGdjcXJVNEc0OEtKaHljaEJxXzVyS0lHdHJnQzA5MXZsS1paZURKRX…
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQdVBrZXFHZnduQlhvTHN1ZDlHbnBlcG9LQ0FscXNyeFN3TjI5M3NCOEFpZThLUXNtc19IWXJJcEZxWEJnb19Zdy1YTWF2cDFnWVlhbUFYQzBPQi1hU3JFeFhjNnFscnJYY3VxSFdYZ0FMdnpLUHFMaUVjQ0lzU0xfT2VpSmRIQURvM0RYT3…
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A High-Growth Stock with Strong Technical Setup - ChartMill
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPdHRBdUlCbzFyQ2taNXdsTWhyaVRVQVNHUDN4eGdZb0dEazB5UDY2VmFPb2NWVzlCamE5V1ozUGlURG9OOWR4dG9PdkVTdUJwN0lPck9HQkt2SmxNOVlsc3AzSjRKRkFRS0tKWlFwa1ExdFlDM1Q1ejhzV1JVSW5CU2VIZFJZajBfaUFjaG…
$KNSA stock is up 21% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNbFFKSlRnWXNnMW82Q0s0OHpac0h2M0VmMU83MmhhamZlZ0ZkNl9FZzlDTlZXYlJhclNGdVpYV0FpOTdGOFdpMUJkOGdlUTU3SHU1cDNIVkZnaXgyZjhJbUI2cHJ4T0FEek5MYWhCaGkyWjNCbXduNXBRYUpmLVVwTlloeVFsUmlHYzVMek…
KNSA — Frequently Asked Questions
What is the current share price of KNSA?
As of 2026-08-05 17:25 PDT, KNSA trades at $78.08 on NASDAQ/NYSE. Its 52-week range is $32.15 to $80.92.
What is the P/E ratio of KNSA?
KNSA trades at a trailing price-to-earnings (P/E) ratio of 104.11.
What is the return on equity (ROE) of KNSA?
KNSA has a return on equity (ROE) of 10.40%. Its return on capital employed (ROCE) is 12.37%.
Is KNSA a good stock to buy?
This page provides a data-driven analysis of KNSA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.